 With this agreement, Ariad received $125 million in upfront payments from Merck and $53 million in milestone payments.Future payments are triggered upon acceptance of the NDA by the FDA with another payment when the drug receives marketing approval.There are similar milestones for acceptance and approval in both Europe and Japan.